The Leukocyte-common antigen related (LAR) receptor regulates different facets of neural development, including cell migration, axon guidance and synapse formation. We have demonstrated that the C. elegans LAR homologue,
ptp-3 functions at neuromuscular junctions to maintain the proper morphology of synaptic domains, including the vesicle clustering region and the active zone. The
ptp-3 locus encodes for at least two distinct proteins, LAR-A and LAR-B, which differ in the extracellular domain, and our analyses indicate that PTP-3A is the only isoform active at synapses. To understand how PTP-3A functions at synapses we have undertaken a structure-function analysis. We have deleted predicted protein motifs from the PTP-3A specific part of the extracellular domain and are testing their ability to rescue the synaptic morphology defects present in
ptp-3 null animals. We have targeted the 3 N-terminal immunoglobulin (Ig) repeats, as well as two of the fibronectin type III (FNIII) repeats. The Ig repeats of another type IIa RPTP, PTPs, were shown to bind specifically to heparan sulfated proteoglycans, where as the 5th FNIII repeat of vertebrate LAR was found to be able to immunoprecipitate the laminin-nidogen complex in vitro. We will present data looking at the localization of the deletion constructs, their effect on the size and shape of active zones and vesicle clustering domains and on behavioral measures of synaptic transmission. A second question we are asking is the function of the intracellular phosphatase domains. A PTP-3A transgene lacking the intracellular domain (ICD) is incapable of rescuing the synaptic defects. To know if this is a structural role for PTP-3A at the synapse or whether the catalytic phosphatase activity was necessary, we have generated mutations in the phosphatase domains. We have found that in an in vitro phosphatase assay that mutations in the first phosphatase domain (C1) result in approximately a 10-fold loss of activity relative to the intact C1 domain. The second phosphatase domain in LAR-like RPTPs has been shown to be catalytically inactive. We have mutated this domain to have the necessary residues to be active. This protein shows approximately 60-fold more activity in the phosphatase assay. We will generate lines of animals with either the hypoactive or hyperactive version of PTP-3A in the
ptp-3 null background and evaluate the effect on synaptic morphology and function.